Ivor Elrifi
CEO & Executive Director
Well, welcome, everybody. Today, we’re here. It’s a lovely day, November 9. We’re here to talk about our Phase II results in the INFORM-MS trial, which was a Phase II placebo-controlled double-blind trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis, and we refer to that as NASPMS.
I’m Ivor Elrifi. I’m the CEO of Tiziana Life Sciences. And today, I have with me a number of our key opinion leaders. Before I get there, I have to just dispense with some legalities. So please, because we’re a publicly traded company, read the forward-looking statements and govern yourselves accordingly. Let me introduce the presenters. The first is Dr. Tanuja Chitnis. Tanuja is the principal investigator of the INFORM-MS trial.
She’s a Professor of Neurology at Harvard Medical School and Brigham and Women’s Hospital. We also have with us Dr. Tarun Singhal. Tarun is the Founding Director of the NeuroPET program at the Ann Romney Center for Neurologic Diseases, which is associated with the Brigham and Women’s Hospital and Mass General Brigham. And he is also an Associate Professor of Neurology at Harvard Medical School.
And lastly, but not least, of course, is Dr. Howard Weiner. Dr. Weiner is the Chair of Tiziana’s Science Advisory Board. He’s Robert Kroc, Professor of Neurology at Harvard Medical School, and he’s the Co-Director of the Ann Romney Center for Neurologic Diseases at BWH. So without further ado, I will turn it over to the investigators to the key opinion
#Tiziana #Life #Sciences #TLSA #Discusses #Positive #Phase #INFORMMS #Results #Intranasal #Foralumab #Nonactive #Secondary #Progressive #Multiple #Sclerosis #Transcript